In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.
News|Articles|July 7, 2026
Q2 2026 Recap: Dermatology News & Updates
Author(s)Tim Smith
Fact checked by: Ryan Livingston
This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.
Advertisement
Advertisement
During the second quarter of 2026, a series of notable events took place in the field of dermatology, including the release of emerging clinical data, new regulatory advancements, and the general evolution of treatment paradigms, reshaping the management of inflammatory skin diseases. Stories regarding new
Related to this article
An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.
From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.
Tilrekimig, a trispecific IL-4/IL-13/TSLP antibody, met its EASI-75 primary endpoint at all doses in a phase 2 atopic dermatitis trial.
Zasocitinib achieved PASI 100 in 36.5% of patients vs 13.9% with deucravacitinib at week 16 in the phase 3 LATITUDE Atlas psoriasis trial.
Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.
Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.
Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.
Advertisement
Advertisement